Anaphylactic shock caused by haemocoagulase injection in China.

Exp Ther Med

Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China.

Published: April 2017

Haemocoagulase injection is a mixture of purified enzymes isolated from the venom of , which is used for the prevention and treatment of haemorrhage. It is a relatively safe pharmacological agent that does not require a skin test prior to administration. However, following a literature search, 14 reported cases of anaphylactic shock caused by haemocoagulase injection were identified, including one lethal case in China. Using SDS-PAGE and protein identification, four primary components in haemocoagulase injection were characterized, including one metalloproteinase, which may be a thromboplastin-like enzyme, and two serine proteinases, which may be thrombin-like enzymes. Administering concentrated haemocoagulase injections failed to provoke a positive skin reaction in allergic patients. Basophil activation tests revealed that haemocoagulase injections did not upregulate cluster of differentiation 63 or C-C chemokine receptor type 3 expression. These findings suggest that haemocoagulase injection may cause fetal anaphylaxis. Although it is difficult to determine a clear conclusion without being able to evaluate the patients that underwent haemocoagulase injection-induced shock, it is unlikely that the venomous components of haemocoagulase injection cross-react with common allergens in allergic patients. It is possible that haemocoagulase injection-induced anaphylaxis is caused by its additive components, such as mannitol and succinylated gelatin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377524PMC
http://dx.doi.org/10.3892/etm.2017.4121DOI Listing

Publication Analysis

Top Keywords

haemocoagulase injection
24
haemocoagulase
10
anaphylactic shock
8
shock caused
8
caused haemocoagulase
8
components haemocoagulase
8
haemocoagulase injections
8
allergic patients
8
haemocoagulase injection-induced
8
injection
6

Similar Publications

Aim: To determine whether the injection of haemocoagulase into the biopsy tract can reduce pneumothorax and pulmonary haemorrhage after computed tomography (CT)-guided percutaneous transthoracic lung biopsy (PTLB).

Materials And Methods: A retrospective study was performed involving patients with undiagnosed pulmonary lesions scheduled for PTLB between January 2020 and March 2021. Patients were assigned to the haemocoagulase group or the non-haemocoagulase group.

View Article and Find Full Text PDF

Objectives: To compare the clinical outcomes of using different hemostatic agents after transurethral plasmakinetic resection of the prostate (TUPKP) in benign prostatic hyperplasia (BPH) patients.

Methods: The patients were divided into 5 groups according to the hemostatic agents used after TUPKP, including the haemocoagulase agkistrodon for injection (HCA), hemocoagulase for injection (HC), hemocoagulase bothrops atrox for injection (HCB), ethylenediamine diaceturate injection (EDD), and tranexamic acid (TXA). Propensity score matching was performed based on age, body mass index, prostate volume, hypertension status, fasting blood glucose, smoking, and drinking history.

View Article and Find Full Text PDF

Anaphylactic shock caused by haemocoagulase injection in China.

Exp Ther Med

April 2017

Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China.

Haemocoagulase injection is a mixture of purified enzymes isolated from the venom of , which is used for the prevention and treatment of haemorrhage. It is a relatively safe pharmacological agent that does not require a skin test prior to administration. However, following a literature search, 14 reported cases of anaphylactic shock caused by haemocoagulase injection were identified, including one lethal case in China.

View Article and Find Full Text PDF

The objective of this study was to evaluate the clinical application of hemostatic percutaneous therapy of liver and spleen trauma under contrast-enhanced ultrasound (CEUS) guidance. A total of 83 patients with 88 traumatic organ lesions were included in this study. Liver or spleen lesions were treated by percutaneous injection of haemocoagulase atrox and α-cyanoacrylate under CEUS guidance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!